ADMA Biologics Inc
NASDAQ:ADMA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.36
22.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
ADMA Biologics Inc
Wall Street
Price Targets
ADMA Price Targets Summary
ADMA Biologics Inc
According to Wall Street analysts, the average 1-year price target for
ADMA
is 23.91 USD
with a low forecast of 17.4 USD and a high forecast of 27.3 USD.
ADMA Last Price Targets
ADMA Biologics Inc
The latest public price target was made on Oct 14, 2024 by
Raghuram Selvaraju
from
H.C. Wainwright
,
who expects
ADMA
stock to
rise by 3%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Raghuram Selvaraju
H.C. Wainwright
|
18
USD
Upside 3% |
2 months ago
Oct 14, 2024
|
H.C. Wainwright Reiterates Buy Rating on ADMA Biologics (ADMA)
StreetInsider
|
Anthony Petrone
Mizuho Securities
|
14
USD
Downside 20% |
6 months ago
Jun 20, 2024
|
ADMA Biologics (ADMA) PT Raised to $14 at Mizuho
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ADMA's stock price target?
Price Target
23.91
USD
According to Wall Street analysts, the average 1-year price target for
ADMA
is 23.91 USD
with a low forecast of 17.4 USD and a high forecast of 27.3 USD.
What is ADMA Biologics Inc's Revenue forecast?
Projected CAGR
30%
For the last 8 years the
compound annual growth rate for
ADMA Biologics Inc's revenue is
56%.
The projected
CAGR
for the next 4 years is
30%.
What is ADMA Biologics Inc's Operating Income forecast?
Projected CAGR
96%
The
compound annual growth rate
of ADMA Biologics Inc's operating income for the next 4 years is
96%.
You don't have any saved screeners yet
